FREE Case Review (866) 588-0600

Onglyza Lawsuit Filed in Texas

A man who allegedly developed heart failure from Onglyza, a type 2 diabetes medicine made by AstraZeneca, has filed a lawsuit in federal court in Texas.

A Texas man has filed a products liability lawsuit against AstraZeneca and Bristol-Myers Squibb alleging that the type 2 diabetes medication Onglyza (generic: saxagliptin) caused him to develop heart failure.

Free Confidential Lawsuit Evaluation: If you or a loved one suffered pancreatic cancer, heart failure or wrongful death after taking Onglyza, you should contact our law firm immediately. You may be entitled to compensation by filing a suit and our lawyers can help.

What’s the Problem?

March 20, 2017 – According to the lawsuit (PDF), Plaintiff Wrendell Chester took both Onglyza and Kombiglyze XR (saxagliptin and metformin) from 2010 to 2015. After taking the medications, he allegedly suffered congestive heart failure, heart failure and acute hypoxic respiratory failure, a condition that results from inadequate gas exchange by the respiratory system.

Chester claims the manufacturers were negligent, manufactured a defective product and failed to warn about the risks.

“Defendants acted in concert with one another to fraudulently convey false and misleading information concerning the safety and efficacy of Saxagliptin and to conceal the risks of serious adverse events, including heart failure, congestive heart failure, cardiac failure, death from heart failure and other adverse effects associated with Saxagliptin from the public, Plaintiff, physicians, and other healthcare providers,” the complaint states. “These concerted efforts resulted in significant harm to those treated with Saxagliptin, including Plaintiff.”

The lawsuit was filed on Feb. 1, 2017, in the U.S. District Court for the Southern District of Texas.

Onglyza and Kombiglyze XR belong to a class of type 2 diabetes drugs called DPP-4 inhibitors that control blood sugar by helping the pancreas produce more insulin after meals and reducing the amount of glucose (sugar) produced by the liver. DPP-4 inhibitors are popular because they don’t encourage weight gain like many other type 2 diabetes medications.

In April 2016, the U.S. Food & Drug Administration (FDA) announced new warnings to the labels of saxagliptin and alogliptin-containing type 2 diabetes medications. FDA said the drugs “may increase the risk of heart failure, particularly in patients who already have heart or kidney disease.” The announcement came 2 years after an FDA panel recommended that the drugs’ labeling should be updated, but did not recommend any other harsher measures.

Do I Have an Onglyza Lawsuit?

The Pharmaceutical Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Onglyza lawsuits. We are handling individual litigation nationwide and currently accepting new pancreatic cancer, heart failure and wrongful death cases in all 50 states.

Free Case Evaluation: Again, if you were injured by Onglyza side effects, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.

Free Confidential Case Evaluation

Verified 100% Secure SiteTo contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (866) 588-0600.
Awards & recognition